PL3634417T3 - Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem - Google Patents
Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworemInfo
- Publication number
- PL3634417T3 PL3634417T3 PL18803171.0T PL18803171T PL3634417T3 PL 3634417 T3 PL3634417 T3 PL 3634417T3 PL 18803171 T PL18803171 T PL 18803171T PL 3634417 T3 PL3634417 T3 PL 3634417T3
- Authority
- PL
- Poland
- Prior art keywords
- quinazoline
- cancer
- treatment
- related disorders
- pyrazole derivatives
- Prior art date
Links
- ARMQQOXIHQRINP-UHFFFAOYSA-N 1H-pyrazole quinazoline Chemical class C=1C=NNC=1.N1=CN=CC2=CC=CC=C21 ARMQQOXIHQRINP-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507540P | 2017-05-17 | 2017-05-17 | |
| PCT/US2018/032868 WO2018213377A1 (en) | 2017-05-17 | 2018-05-16 | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3634417T3 true PL3634417T3 (pl) | 2023-09-25 |
Family
ID=64274816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18803171.0T PL3634417T3 (pl) | 2017-05-17 | 2018-05-16 | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11220492B2 (https=) |
| EP (1) | EP3634417B1 (https=) |
| JP (1) | JP7189155B2 (https=) |
| CN (1) | CN110636846B (https=) |
| ES (1) | ES2951809T3 (https=) |
| PL (1) | PL3634417T3 (https=) |
| WO (1) | WO2018213377A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR117844A1 (es) * | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
| CN113795267A (zh) | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| WO2020205527A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CN119118872A (zh) | 2020-03-19 | 2024-12-13 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| KR20230026312A (ko) | 2020-06-17 | 2023-02-24 | 아르커스 바이오사이언시즈 인코포레이티드 | Cd73 억제제의 결정형 및 이의 용도 |
| CN112326961B (zh) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备 |
| CN112691107B (zh) * | 2021-02-03 | 2022-09-02 | 北京斯利安药业有限公司 | 一种药物组合物及其应用 |
| WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| CN113642386B (zh) * | 2021-07-02 | 2024-06-21 | 广州金域医学检验中心有限公司 | 基于深度学习评价鼻咽癌治疗效果的方法、装置、设备和介质 |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| US20240180947A1 (en) | 2022-10-20 | 2024-06-06 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4720055A1 (en) | 2023-05-25 | 2026-04-08 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN119139469A (zh) * | 2023-06-16 | 2024-12-17 | 武汉大学 | 腺苷受体抑制剂在制备用于治疗高脂血症与心脑血管疾病的药物中的应用 |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
| WO2026035034A1 (ko) * | 2024-08-06 | 2026-02-12 | 주식회사 대웅제약 | 신규한 퀴나졸린 유도체 및 이를 포함하는 약학 조성물 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE205202T1 (de) | 1992-03-13 | 2001-09-15 | Merck Sharp & Dohme | Imidazol-, triazol- und tetrazolderivate |
| GB9207396D0 (en) | 1992-04-03 | 1992-05-13 | Merck Sharp & Dohme | Therapeutic agents |
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| EP1399467A4 (en) | 2001-05-09 | 2004-09-15 | Newbiotics Inc | PRODRUGS ACTIVATED BY PEPTIDDEFORMYLASE |
| US6642390B2 (en) | 2001-07-11 | 2003-11-04 | Lexicon Pharmaceuticals, Inc. | One step synthesis of 1,2,3-triazole carboxylic acids |
| DE60222698T2 (de) | 2001-12-18 | 2008-06-19 | Merck & Co., Inc. | Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5 |
| JP2005529889A (ja) | 2002-04-26 | 2005-10-06 | ファイザー・プロダクツ・インク | ピリミジン−２，４，６−トリオンメタロ−プロテイナーゼ阻害剤 |
| US7354938B2 (en) | 2004-03-23 | 2008-04-08 | Amgen Inc. | Pyrazole compounds and uses related thereto |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JP4734346B2 (ja) | 2005-02-04 | 2011-07-27 | セノミックス インコーポレイテッド | 連結ヘテロアリール部分を含む化合物、ならびに食用組成物のための新規なうまみフレーバー改変剤、味物質および味覚増強剤としての使用 |
| US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007109547A2 (en) * | 2006-03-17 | 2007-09-27 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| US20080032992A1 (en) | 2006-07-04 | 2008-02-07 | Astrazeneca Ab | New Pyridine Analogues V |
| US7994321B2 (en) | 2006-08-08 | 2011-08-09 | Hoffmann-La Roche Inc. | Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| PE20091953A1 (es) | 2008-05-08 | 2010-01-09 | Du Pont | Azoles sustituidos como fungicidas |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| US20120040974A1 (en) | 2008-08-18 | 2012-02-16 | Yale University | Mif modulators |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| RU2528412C2 (ru) * | 2009-02-10 | 2014-09-20 | Янссен Фармацевтика Нв | Хиназолиноны как ингибиторы пролилгидроксилазы |
| US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
| US8193235B2 (en) | 2009-06-12 | 2012-06-05 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| EP2451286B8 (en) | 2009-07-08 | 2018-04-04 | ISP Investments LLC | 4- and 5 substituted 1,2,3- triazole moieties with at least one remote polymerizable moiety and polymers thereof |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| WO2011050284A1 (en) | 2009-10-23 | 2011-04-28 | Glaxosmithkline Llc | Pyrazolylpyridine antiviral agents |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| CN102918034B (zh) | 2010-03-30 | 2015-06-03 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| US8748435B2 (en) | 2011-04-01 | 2014-06-10 | Novartis Ag | Pyrazolo pyrimidine derivatives |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013085890A1 (en) | 2011-12-06 | 2013-06-13 | Glaxo Group Limited | Therapeutic methods |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| RU2627268C2 (ru) | 2012-02-29 | 2017-08-04 | Хемоцентрикс, Инк. | Аза-арил-1Н-пиразол-1-ил-сульфонамиды |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| DE102012102162A1 (de) | 2012-03-14 | 2013-09-19 | Westfälische Wilhelms-Universität Münster Körperschaft des öffentlichen Rechts | Ionenleitende polymere Verbindung für elektrochemische Zellen |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014153100A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2015031824A1 (en) | 2013-08-30 | 2015-03-05 | Icahn School Of Medicine At Mount Sinai | Cyclic vinylogous amides as bromodomain inhibitors |
| EP2903044A1 (de) | 2014-02-04 | 2015-08-05 | cynora GmbH | Organische Moleküle zur Verwendung in optoelektronischen Bauelementen |
| EP3137074B1 (en) | 2014-04-29 | 2020-08-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| US20160251341A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted triazole compounds as serine protease inhibitors |
| CN108472284A (zh) | 2015-09-11 | 2018-08-31 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| HUE064141T2 (hu) | 2017-01-20 | 2024-02-28 | Arcus Biosciences Inc | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére |
| ES2953349T3 (es) * | 2017-05-05 | 2023-11-10 | Arcus Biosciences Inc | Derivados de quinazolina-piridina para el tratamiento de trastornos relacionados con el cáncer |
-
2018
- 2018-05-16 PL PL18803171.0T patent/PL3634417T3/pl unknown
- 2018-05-16 ES ES18803171T patent/ES2951809T3/es active Active
- 2018-05-16 EP EP18803171.0A patent/EP3634417B1/en active Active
- 2018-05-16 US US16/614,063 patent/US11220492B2/en active Active
- 2018-05-16 WO PCT/US2018/032868 patent/WO2018213377A1/en not_active Ceased
- 2018-05-16 CN CN201880032987.1A patent/CN110636846B/zh active Active
- 2018-05-16 JP JP2019563142A patent/JP7189155B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3634417C0 (en) | 2023-07-12 |
| JP7189155B2 (ja) | 2022-12-13 |
| JP2020519664A (ja) | 2020-07-02 |
| WO2018213377A1 (en) | 2018-11-22 |
| ES2951809T3 (es) | 2023-10-25 |
| EP3634417B1 (en) | 2023-07-12 |
| CN110636846A (zh) | 2019-12-31 |
| US20210214346A1 (en) | 2021-07-15 |
| EP3634417A4 (en) | 2021-01-13 |
| CN110636846B (zh) | 2023-05-16 |
| US11220492B2 (en) | 2022-01-11 |
| EP3634417A1 (en) | 2020-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| EP3618829C0 (en) | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-ASSOCIATED DISORDERS | |
| PL3634417T3 (pl) | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem | |
| ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL256224B (en) | Combined therapy for cancer treatment | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL258521A (en) | Combination of treatments for cancer treatment | |
| IL259996A (en) | Combinations for cancer treatment | |
| IL267818A (en) | Methods for treating neurological disorders | |
| IL258032A (en) | Compounds and preparations for the treatment of ocular disorders | |
| IL249502A0 (en) | Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| IL259674B (en) | Benzofuran derivatives for the treatment of diseases related to the central nervous system and other diseases | |
| IL266993A (en) | Combined therapy for cancer treatment | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
| IL273835A (en) | Combined product for cancer treatment | |
| PL3630754T3 (pl) | Związki izoindolinoacetylenowe do leczenia nowotworu | |
| EP3371154A4 (en) | HETEROCYCLIC DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | |
| EP3507277B8 (en) | Hydroxynorketamine derivatives for the treatment of disorders | |
| IL253642A0 (en) | Combined treatment for cancer | |
| PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
| HK1260601A1 (en) | Heterocycle derivatives and their use for the treatment of cns disorders |